Effect of Cilostazol in Platelet Inhibition in Patients With Peripheral Artery Disease

Cilostazol is a quinolone derivate known mainly for its vasodilatory properties and its use in the treatment of intermittent claudication in patients with peripheral artery disease. Cilostazol is a phosphodiesterase III inhibitor that increases cAMP in platelets and blood vessels, increasing protein kinase A levels which is related to platelet inhibition. The emergence of viscoelastic assays, such as thromboelastography with platelet mapping, have been utilized to identify prothrombotic states and may provide insight into a patient's microvascular coagulation profile.

Source: Journal of Vascular Surgery - May 23, 2023 Category: Surgery Authors: Sasha P. Suarez Ferreira, Ryan Hall, Monica Majumdar, Guillaume Goudot, Samuel Jessula, Zach M. Feldman, Tiffany Bellomo, Ivy Lee, Lois Owolabi, Amanda Kirshkaln-Leahy, Kathryn Nuzzolo, Anahita Dua Tags: Poster Competition Source Type: research